For healthcare professionals only
diabetes on the net

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

  • Focus on: Elderly and frail

DID YOU KNOW?

Compared with other age groups, the elderly and frail are at an increased risk of developing type 2 diabetes.6,7

Healthcare professionals should assess frailty in their older patients and be aware of the potential need to adjust glycaemic targets in this population.8,9

Click here to find out more

Proven efficacy vs placebo1,10

Proven efficacy vs placebo1,10: The efficacy and safety of 5 mg linagliptin was evaluated in eight phase III randomised controlled trials. Linagliptin once daily demonstrated clinically significant improvements in glycaemic control vs placebo or comparator.1

Demonstrated CV and kidney safety profile

Long-term cardiovascular and kidney safety profile of TRAJENTA® has been demonstrated in two cardiovascular outcome trials.11⁠–⁠17 As TRAJENTA® is primarily excreted via the bile, it is suitable for a broad range of adults with type 2 diabetes independent of renal function.1

Unique convenience of one dose, once daily1

The recommended dose of TRAJENTA® for adult patients with type 2 diabetes is 5 mg once daily, independent of renal and hepatic function, body mass index, age, ethnicity, background type 2 diabetes therapy, and disease duration.1,17

  • Webinar

Sarah Jarvis
Webinar Series Chair

To view the most recent webinar

Click here
  • VIRTUAL WEBINARS
References:
  1. TRAJENTA® (linagliptin) Summary of Product Characteristics (SmPC).*
  2. Sitagliptin SmPC.*
  3. Vildagliptin SmPC.*
  4. Saxagliptin SmPC.*
  5. Alogliptin SmPC.**
  6. Mendola ND, et al. NCHS data brief 2018;319:1–8.
  7. Kirkman MS, et al. Diabetes Care. 2012;35:2650–64.
  8. Strain WD, et al. Diabet Med. 2018;35:838–45.
  9. Strain WD, et al. Diabetes Ther. 2021;12:1227–47.
  10. McGill JB, et al. Diabetes Care. 2013;36:237–44.
  11. Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
  1. Rosenstock J, et al. JAMA. 2019;321:69–79.
  2. Cooper M, et al. Diabetes Obes Metab. 2020;22:1062–73.
  3. Marx N, et al. Diab Vasc Res. 2015;12:164–74.
  4. Rosenstock J, et al. JAMA. 2019;322:1155–66.
  5. Espeland MA, et al. Diabetes Obes Metab. 2021;23:569–80.
  6. Lajara R, et al. Clin Ther. 2014;36:1595–605.

*Summary of Product Characteristics for Trajenta, sitagliptin, vildagliptin and saxagliptin are available at: https://www.medicines.org.uk (GB), https://www.emcmedicines.com/en-GB/northernireland/ (NI) and https://www.medicines.ie/ (ROI).

**Summary of Product Characteristics for alogliptin are available at: https://www.medicines.org.uk (GB) and https://www.emcmedicines.com/en-GB/northernireland/ (NI).

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-106627 V7 | March 2024

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland 

This website is for healthcare professionals in Great Britain, Northern Ireland and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in Great Britain, Northern Ireland or the Republic of Ireland by clicking below.
I am
I am not
Prescribing information for Great Britain and Northern Ireland
Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].


NICE Technology Appraisal Guidance: Tirzepatide (tirzepatide) for treating type 2 diabetes10

Tirzepatide is recommended for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if:

  • triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and
  • they have a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or
  • they have a BMI of less than 35 kg/m2, and:
    • insulin therapy would have significant occupational implications, or
    • weight loss would benefit other significant obesity-related complications

 

Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for peoplefrom South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.

See NICE TA924

Prescribing information and adverse event reporting for Mounjaro® (tirzepatide) (external link)

Reference: 10. © NICE 2023 Tirzepatide for treating type 2 diabetes. Available from https://www.nice.org.uk/guidance/TA924. Accessed March 2024. All rights reserved. Subject to Notice of rights.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
CLOSE

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel
For healthcare professionals only
GP Notebook

Are you a healthcare professional?

The information is intended for healthcare professionals only.
Please confirm below.

No
Yes